Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Section 3 of 6

Product information and disease description

298 evidence topics · 147 sources

Product description

Phase of product development

Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027
Expedited program designations

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Nonproprietary name

No evidence found.

Chemical structure, molecular formula, and molecular weight

No evidence found.

Dosage forms and strengths
Commercial strengths, package configuration, and national drug code

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification

Not applicable.

Indication
Proposed U.S. labeled indication

No evidence found.

Pharmacology
Mechanism of action
Peptide sequence, structure, and oral absorption technology

No evidence found.

Pharmacodynamics
Subcutaneous formulation: fasting glucose, HbA1c, and blood pressure at week 13 in the phase 2 trial
Subcutaneous formulation: weight loss persisting after the last dose in the phase 2 trial
Gastric emptying, energy intake, and body composition in humans

No evidence found.

Pharmacokinetics
Subcutaneous formulation: pharmacokinetic parameters at 5.0 mg weekly in the phase 2 trial
DoseCmax (ng/mL)AUC0-168 (ng*h/mL)T1/2 (h)
VK2735 5.0 mg“1,120”“158,000”“171”
Oral formulation: bioavailability, half-life, and food effect

No evidence found.

Distribution, metabolism, and elimination pathways

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Approved prescribing information, boxed warnings, contraindications, and REMS

Not applicable.

Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial
Event, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
TEAE leading to treatment discontinuation“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote
Treatment-emergent serious adverse events“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Pancreatitis“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Gallbladder associated events“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Injection site reactions“3 (9)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study
Event, number of subjects (%)Placebo (n=19)2.5 mg (n=8)5 mg (n=7)10 mg (n=6)20 mg (n=8)40 mg (n=8)60 mg (n=9)80 mg A (n=9)80 mg B (n=9)100 mg (n=9)
Drug related TEAEs“11 (58%)”“4 (50%)”“4 (57%)”“3 (50%)”“4 (50%)”“7 (88%)”“6 (67%)”“9 (100%)”“7 (78%)”“9 (100%)”
Serious adverse events“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“1 (11%)”“0 (0%)”“0 (0%)”“0 (0%)”
Special populations
Pediatric participants: clinical data with either formulation

No evidence found.

Renal or hepatic impairment: pharmacokinetic data with either formulation

No evidence found.

Pregnancy and lactation: clinical data with either formulation

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on VK2735
Clinical drug interaction studies with either formulation

No evidence found.

Metabolic pathway of VK2735

No evidence found.

Oral formulation: effect of food or co-administered drugs on tablet absorption

No evidence found.

Effects of VK2735 on other drugs
Clinical drug interaction studies with either formulation

No evidence found.

Effect of VK2735 on gastric emptying and absorption of oral medications

No evidence found.

Dosing and administration
Dosage
Proposed labeled dose, titration, and dose modification

No evidence found.

Administration
Instructions for use, injection sites, and storage

No evidence found.

Oral formulation: administration relative to food, water, and other oral medications

No evidence found.

Access and distribution
Planned distribution channels: cash pay, direct-to-consumer, and direct-to-employer
Specialty pharmacy or distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Effect of VK2735 on quality measures
Product-specific effect on quality measures

No evidence found.

Healthy People 2030 objective NWS-03: proportion of adults with obesity
Product comparison

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Chronic weight management
Prevalence of Chronic weight management
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Body mass index categories for adults
BMI categoryBMI range (kg/m2)
Underweight“Less than 18.5”
Healthy weight“18.5 to less than 25”
Overweight“25 to less than 30”
Class 1 obesity“30 to less than 35”
Class 2 obesity“35 to less than 40”
Class 3 obesity (severe obesity)“40 or greater”
Screening and confirmation of excess adiposity: ADA Standards of Care
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Chronic weight management
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Economic impact of Chronic weight management on families

Not applicable.

Economic impact of diagnostic testing

Not applicable.

Approaches to treatment

Current treatment options and standard of care
Lifestyle and behavioral interventions
GLP-1 receptor agonists
Semaglutide injection and tablets: wholesale acquisition cost
Product and packageQuoted WAC price
Tablets, 25 mg, 30 tablets per bottle“$1,349.02”
Injection, 2.4 mg dose, 4-pen package“$1,349.02”
Wegovy HD injection, 7.2 mg dose, 4-pen package“$1,349.02”
Dual GIP and GLP-1 receptor agonists
Tirzepatide: average wholesale price and National Average Drug Acquisition Cost
Oral small-molecule GLP-1 receptor agonists
Other anti-obesity medications
Metabolic and bariatric surgery
Limitations of current therapies
Summary: limitations of current therapies

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.

Place in treatment, anticipated use, and care setting
Summary: anticipated place in treatment

VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.

Heterogeneity of treatment effect
Subcutaneous formulation: BMI category change by baseline obesity class in VENTURE
Baseline BMI categoryVK2735 participants (n)Placebo participants (n)VK2735: no change in obesity classPlacebo: no change in obesity class
Class III obesity“n=35”“n=15”“31 %”“87 %”
Class II obesity“n=51”“n=10”“18 %”“80 %”
Class I obesity“n=46”“n=8”“26 %”“75%”
Care management intervention strategies
BALANCE Model: negotiated prices, lifestyle support, and product eligibility
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy